Feedback

Redefining RRMM Care: Visual Pathways

Question 1 of 24

What is the recommended strategy for intravenous immunoglobulin (IVIG) replacement in patients starting continuous BCMA-directed bispecific antibody therapy to minimize infection risk?

A) Initiate IVIG supplementation only if serum IgG levels fall below 200 mg/dL.

B) Administer primary prophylaxis with IVIG, typically starting on Cycle 2 Day 1, to maintain IgG levels above 400 mg/dL.

C) Provide secondary prophylaxis with IVIG only after the first instance of a grade 3 or higher respiratory infection.

D) Administer IVIG strictly prior to step-up dosing and discontinue once a Very Good Partial Response (VGPR) is achieved.

E) Utilize IVIG only for patients who do not receive prophylactic tocilizumab during the step-up phase.